High acceptability and satisfaction with NuvaRing use

European Journal of Contraception and Reproductive Health Care

Volumn 7, Issue SUPPL. 2, 2002, Pages 31-36

  Szarewski, A ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Acceptability; Contraception; NuvaRing; Satisfaction; Vaginal ring

Indexed keywords

ETHINYLESTRADIOL PLUS ETONOGESTREL;

ADULT; CONFERENCE PAPER; CONTRACEPTION; CONTROLLED STUDY; DRUG USE; DYSMENORRHEA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PILL; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; SATISFACTION; SEXUAL INTERCOURSE;

EID: 0037004986     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.1080/13625187.2002.11949333     Document Type: Conference Paper

References (12)

1. Mishell DR, Talas M, Parlow AF, Moyer DL. Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate. Am J Obstet Gynecol 1970;107:100-7
2. Mishell DR, Moore DE, Roy S, Brenner PF, Page MA. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel. Am J Obstet Gynecol 1978;130:55-62
3. Ährén T, Victor A, Lithell H, Vessby B, Jackanicz TM, Johansson ED. Ovarian function, bleeding control and serum lipoproteins in women using contraceptive vaginal rings releasing five different progestins. Contraception 1983;28:315-27
4. Sivin I, Mishell DR, Victor A, Diaz S, Alvarez-Sanchez F, Nielsen NC, et al. A multicenter study of levonorgestrel - estradiol contraceptive vaginal rings. I. Use effectiveness. An international comparative trial. Contraception 1981;24:341-58
5. Jackson R, Newton JR. The in vivo release characteristics of a multi-compartment vaginal ring releasing 3-keto-desogestrel. Contraception 1989;40:615-21
6. Timmer CJ, Apter D, Voortman G. Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released front different types of contraceptive vaginal rings. Contraception 1990;42:629-42
7. Roumen F, Dieben T, Assendorp R, Bouckaert P. The clinical acceptability of a non-medicated vaginal ring. Contraception 1990;42:201-7
8. Timmer CJ, Mulders TMT. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000;39:233-42
9. Mulders TMT, Dieben TOM. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 2001;75:865-70
10. Mulders TMT, Dieben TOM, Coelingh Bennink HJT. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod 2002;17:2594-9
11. Roumen FJME, Apter D, Mulders TMT, Dieben TOM. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonorgestrel and ethinyl oestradiol. Hum Reprod 2001;16:469-75
12. Dieben TOM, Roumen FJME, Apter D. Efficacy, cycle control and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002;100:585-93